These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 23278124

  • 1. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [Abstract] [Full Text] [Related]

  • 2. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 4. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Apr 10; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V.
    Br J Haematol; 2010 Feb 10; 148(3):466-75. PubMed ID: 19912219
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.
    Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Mahdavi M, Alipour A, Aliasgharian A.
    Phytother Res; 2018 Mar 10; 32(3):496-503. PubMed ID: 29235162
    [Abstract] [Full Text] [Related]

  • 11. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic value of combined therapy with deferiprone and silymarin as iron chelators in Egyptian children with beta thalassemia major.
    Hagag AA, Elfaragy MS, Elrifaey SM, Abd El-Lateef AE.
    Infect Disord Drug Targets; 2015 Jan 01; 15(3):189-95. PubMed ID: 26239735
    [Abstract] [Full Text] [Related]

  • 13. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
    Wu SF, Peng CT, Wu KH, Tsai CH.
    Hemoglobin; 2006 Jan 01; 30(2):215-8. PubMed ID: 16798646
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K, Tzoumari I, Pappa C.
    Blood Cells Mol Dis; 2011 Jun 15; 47(1):33-40. PubMed ID: 21531154
    [Abstract] [Full Text] [Related]

  • 16. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan 15; 23(1):48-56. PubMed ID: 22943064
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunomodulatory effects of silymarin in patients with β-thalassemia major.
    Gharagozloo M, Karimi M, Amirghofran Z.
    Int Immunopharmacol; 2013 Jun 15; 16(2):243-7. PubMed ID: 23624215
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluating the safety and efficacy of silymarin in β-thalassemia patients: a review.
    Moayedi Esfahani BA, Reisi N, Mirmoghtadaei M.
    Hemoglobin; 2015 Jun 15; 39(2):75-80. PubMed ID: 25643967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.